Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-00610355. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-00610355 SCHEMBL2452493 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3 | |
| Pf-00610355 SCHEMBL29369227 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL2454719 | 0.95 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL2454716 | 0.95 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL12305722 | 0.95 | ADRB2 (0.90) | ADRB2CHRM3 | |
| SCHEMBL2455108 | 0.95 | ADRB2 (0.90) | ADRB2CHRM3 | |
| SCHEMBL2455101 | 0.95 | ADRB2 (0.90) | ADRB2CHRM3 | |
| SCHEMBL2452842 | 0.93 | ADRB2 (0.90) | ADRB2CHRM3 | |
| SCHEMBL2452847 | 0.93 | ADRB2 (0.90) | ADRB2CHRM3 | |
| SCHEMBL2451870 | 0.90 | ADRB2 (0.82) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | claimed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | claimed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | claimed |
| EP-1708991-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | claimed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-1907356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007010356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-1708991-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ADRB2 147/4885CHRM3 167/4885 |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885CHRM3 1774/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | ADRB2 147/4885CHRM3 167/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ADRB2 147/4885CHRM3 167/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | ADRB2 147/4885CHRM3 167/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | ADRB2 119/4885CHRM3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.